ArticleEuropean radiology2025
Annual percentage change of MR Parkinsonism index in progressive supranuclear palsy: a feasibility study.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesConsiderable evidence suggests that midbrain-based magnetic resonance Parkinsonism index (MRPI) measurements are reliable biomarkers for the diagnosis of progressive supranuclear palsy (PSP). However, the longitudinal atrophy pattern of PSP and potential differences in change rates among PSP phenotypic spectrum remain unclear. This study aims to investigate the longitudinal changes of MRPI measurements and explore their potential role in PSP phenotype progression monitoring. MATERIALS AND
methodsThirty-six patients with PSP-Richardson's syndrome (PSP-RS), 21 patients with variant PSP (vPSP), and 21 healthy controls (HCs) with longitudinal MRI and clinical follow-up were enrolled. Midbrain-based morphometric measurements and the corresponding annual percentage changes (APCs) were measured and further used to evaluate the associations with disease progression.
resultsSignificant differences in midbrain-based morphometric biomarkers were observed both at baseline and longitudinal trajectories between PSP and HC groups, but no significant differences were found between PSP-RS and vPSP subgroups. Baseline comprehensive measurements were significantly associated with the baseline PSP rating scale (PSPrs) in all PSP and PSP phenotypes. The APC of MRPI was significantly associated with the APC of PSPrs in all PSP (r = 0.267, p = 0.046) and the PSP-RS subgroup (r = 0.386, p = 0.020).
conclusionsThis study characterizes the longitudinal atrophy trajectory of PSP phenotypes and the significant associations between morphometric measurements and disease severity. Dissecting the causal associations among core 4R-tau, dopamine, and subsequent atrophy trajectories may enhance the application of these biomarkers for phenotype attribution. KEY POINTS: Questions The use of midbrain-based MRPI measurements to assess the longitudinal prognosis of the PSP phenotype remains uncertain. Findings Significant differences in midbrain-based morphometric biomarkers were observed both at baseline and longitudinal trajectories between PSP and health control groups. Clinical relevance Midbrain-based morphometric measurements hold promise as potential radiological biomarkers for monitoring PSP disease progression and assessment.
Indexed as
Identifiers
40000508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.